美国 · SEC FORM 4
IDEXX LABORATORIES INC /DE
IDXX · Nasdaq · CIK 0000874716 · Healthcare · Diagnostics & Research
内部人信号
0 qualifying P purchase groups
当前 180 天评分窗口
15 同一窗口内观察到的 Form 4 交易行
1 sales · 14 期权、代扣税、授予、赠与或其他交易行
为什么没有活跃信号？
评分构成
活跃窗口内没有合资格买入，因此不计算分数。缺失的输入不会被当作零分或看空信号。
为什么没有分数？
- 没有合资格公开市场买入可提供聚集度、规模、角色、近期性或确信度输入。
- 卖出及其他 Form 4 活动继续作为背景显示，不会形成负分。
卖出和其他 Form 4 活动会单独显示，不会形成负面买入信号。没有买入不会被评分为看空。
内部人活动时间轴
申报人轨道展示最近 180 天。符号形状区分交易类型；卖出仅作为背景。
Showing the six most active owners; 2 additional owner(s) remain in Form 4 申报证据.
买方广度、集中度与聚集买入
合资格买入进入 180 天研究窗口后，这些模块才会启用。
信号历史
Scores are archived only when the company qualifies for a published US buy-signal snapshot.—
近期 Form 4 活动
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
市场背景
该股票尚未获取市场背景。每日任务会轮转处理美国股票池。
空头余额
空头余额是券商向 FINRA 申报的外部背景数据，不影响内部人信号。
- 空头股数
- 1,940,639
- 上期报告
- 1,917,016
- 日均成交量
- 496,267
- 回补天数
- 3.9
FINRA 结算日：2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数，每月两个结算日之后约一周公布；不是占已发行股份的比例。
历史股票买入
本地 Form 4 历史中没有合资格的代码 P 股票买入。
Form 4 申报证据
118 transaction lines in the latest 365-day window; 1,177 in local history.
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-09-04 | Kingsley Lawrence D | 卖出 (S) | Common Stock | 2,203 | USD 532.08 | USD 1,172,172 | SEC 申报 ↗ |
| 2026-09-04 | Kingsley Lawrence D | 期权行权／转换 (M) | Common Stock | 2,203 | USD 114.17 | USD 251,517 | SEC 申报 ↗ |
| 2026-08-20 | Emerson Andrew | 期权行权／转换 (M) | Common Stock | 265 | USD 178.26 | USD 47,239 | SEC 申报 ↗ |
展开近期 Form 4 证据 (30 grouped rows)
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-09-04 | Kingsley Lawrence D | 卖出 (S) | Common Stock | 2,203 | USD 532.08 | USD 1,172,172 | SEC 申报 ↗ |
| 2026-09-04 | Kingsley Lawrence D | 期权行权／转换 (M) | Common Stock | 2,203 | USD 114.17 | USD 251,517 | SEC 申报 ↗ |
| 2026-08-20 | Emerson Andrew | 期权行权／转换 (M) | Common Stock | 265 | USD 178.26 | USD 47,239 | SEC 申报 ↗ |
| 2026-08-20 | Emerson Andrew | 代扣税 (F) | Common Stock | 86 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-07-30 | HOOLEY JOSEPH L | 奖励／授予 (A) | Common Stock | 49 | USD 558.80 | USD 27,381 | SEC 申报 ↗ |
| 2026-06-01 | FENNELL GEORGE | 期权行权／转换 (M) | Common Stock | 639 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-06-01 | FENNELL GEORGE | 代扣税 (F) | Common Stock | 284 | USD 566.79 | USD 160,968 | SEC 申报 ↗ |
| 2026-05-07 | Vandebroek Sophie V. | 期权行权／转换 (M) | Common Stock | 257 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-05-07 | SZOSTAK M ANNE | 期权行权／转换 (M) | Common Stock | 257 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-05-07 | Peacock Karen | 期权行权／转换 (M) | Common Stock | 101 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-05-07 | Kingsley Lawrence D | 期权行权／转换 (M) | Common Stock | 339 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-05-07 | JUNIUS DANIEL M | 期权行权／转换 (M) | Common Stock | 257 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-05-07 | HOOLEY JOSEPH L | 期权行权／转换 (M) | Common Stock | 158 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-04-30 | HOOLEY JOSEPH L | 奖励／授予 (A) | Common Stock | 43 | USD 560.80 | USD 24,114 | SEC 申报 ↗ |
| 2026-03-03 | Underberg Sharon E. | 期权行权／转换 (M) | Common Stock | 197 | USD 505.53 | USD 99,589 | SEC 申报 ↗ |
| 2026-03-03 | Hunt Nimrata | 卖出 (S) | Common Stock | 1,758 | USD 634.57 | USD 1,115,574 | SEC 申报 ↗ |
| 2026-02-27 | MAZELSKY JONATHAN JAY | 期权行权／转换 (M) | Common Stock | 197 | USD 505.53 | USD 99,589 | SEC 申报 ↗ |
| 2026-02-26 | MAZELSKY JONATHAN JAY | 卖出 (S) | Common Stock | 23,326 | USD 657.55 | USD 15,338,089 | SEC 申报 ↗ |
| 2026-02-26 | MAZELSKY JONATHAN JAY | 期权行权／转换 (M) | Common Stock | 23,326 | USD 141.60 | USD 3,302,962 | SEC 申报 ↗ |
| 2026-02-26 | Hunt Nimrata | 卖出 (S) | Common Stock | 2,693 | USD 661.54 | USD 1,781,527 | SEC 申报 ↗ |
| 2026-02-19 | Erickson Michael G | 期权行权／转换 (M) | Common Stock | 2,399 | USD 227.83 | USD 546,557 | SEC 申报 ↗ |
| 2026-02-17 | Vandebroek Sophie V. | 卖出 (S) | Common Stock | 1,464 | USD 628.62 | USD 920,297 | SEC 申报 ↗ |
| 2026-02-17 | Vandebroek Sophie V. | 期权行权／转换 (M) | Common Stock | 945 | USD 333.90 | USD 315,536 | SEC 申报 ↗ |
| 2026-02-17 | Erickson Michael G | 卖出 (S) | Common Stock | 5,371 | USD 627.38 | USD 3,369,668 | SEC 申报 ↗ |
| 2026-02-17 | Erickson Michael G | 期权行权／转换 (M) | Common Stock | 5,371 | USD 170.13 | USD 913,772 | SEC 申报 ↗ |
| 2026-02-14 | Underberg Sharon E. | 期权行权／转换 (M) | Common Stock | 832 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-02-14 | Underberg Sharon E. | 代扣税 (F) | Common Stock | 251 | USD 629.35 | USD 157,967 | SEC 申报 ↗ |
| 2026-02-14 | Smith Martin Alexander | 期权行权／转换 (M) | Common Stock | 1,004 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-02-14 | Smith Martin Alexander | 代扣税 (F) | Common Stock | 302 | USD 629.35 | USD 190,064 | SEC 申报 ↗ |
| 2026-02-14 | Schreck Michael | 期权行权／转换 (M) | Common Stock | 1,959 | USD 0.00 | USD 0 | SEC 申报 ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
快照与身份
| 快照日期 | 2026-10-18 |
|---|---|
| 排名版本 | US-v1.2 |
| 数据质量 | PASS ELIGIBLE · — |
| 股票代码 | IDXX |
| CIK | 0000874716 |
| 行业 | Healthcare |
| 细分行业 | Diagnostics & Research Yahoo Finance |
| SEC SIC | 2835 In Vitro & In Vivo Diagnostic Substances |
| 交易所 | Nasdaq |
数据覆盖
| 本地 Form 4 历史 | 1,177 transaction lines from 2020-01-15 to 2026-09-04 0 P purchase lines · 491 S sale lines · 686 other lines |
|---|---|
| SEC 公司申报 | 打开 SEC 申报 ↗ |
Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.